Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intracavitary Allogenic Cytotoxic T Lymphocytes and Human Recombinant Interleukin-2 Therapy for Recurrent Primary Brain Tumors

NCT00002572 is registered in ClinicalTrials.gov with University of Colorado, Denver as lead sponsor.

NCT NCT00002572
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00002572 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intracavitary Allogenic Cytotoxic T Lymphocytes and Human Recombinant Interleukin-2 Therapy for Recurrent Primary Brain Tumors
Lead sponsor
University of Colorado, Denver
Phase
Phase 1
Overall status
Completed
Start date
November 30, 1994
Completion date
December 31, 1999
Enrollment
10 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

brain and central nervous system tumors